Beland Michael D, Gervais Debra A, Levis Diane A, Hahn Peter F, Arellano Ronald S, Mueller Peter R
Department of Radiology, Division of Abdominal Imaging and Intervention, Massachusetts General Hospital, 55 Fruit St, White 270, Boston, MA 02114, USA.
Radiology. 2008 May;247(2):567-73. doi: 10.1148/radiol.2472070761. Epub 2008 Mar 27.
To retrospectively evaluate the effectiveness and safety of tissue-type plasminogen activator (tPA) for drainage of abdominal and pelvic abscesses refractory to simple catheter drainage.
This HIPAA-compliant study was approved by the Institutional Review Board; informed consent was waived. Forty-three patients (17 men, 26 women; mean age, 46 years; age range, 10-89 years) with a total of 46 abscesses underwent percutaneous drainage with 8.5-14-F catheters. Etiology was postoperative in 28 abscesses (60.9%) and varied in 18 (39.1%). Intracavitary tPA was initiated on the basis of viscous contents yielding minimal drainage at initial placement or if follow-up imaging showed a large residual collection despite satisfactory catheter position. A treatment cycle was 4-6 mg of tPA in 0.9% saline administered twice daily for 3 days. Drainage success was defined as evacuation of the abscess without surgery. Safety was evaluated on the basis of complications. Statistical analysis was performed by using the Student t test and Fisher exact test.
Forty-six abscesses were initially drained by 51 catheters. Complete evacuation was achieved in 41 (89.1%) abscesses, whereas five (10.9%) required surgical drainage. Three (60%) of these five had a documented fistula, a higher (P = .02) percentage than in successfully drained abscesses. Three (6.5%) of the 46 abscesses recurred (12-95 days after catheter removal). There were no tPA-linked bleeding complications despite four patients receiving full systemic anticoagulation and 24 receiving prophylactic anticoagulation.
Intracavitary tPA is safe and effective for draining complex fluid collections, with most patients avoiding surgery.
回顾性评估组织型纤溶酶原激活剂(tPA)用于引流经单纯导管引流效果不佳的腹部和盆腔脓肿的有效性和安全性。
本符合健康保险流通与责任法案(HIPAA)的研究经机构审查委员会批准;无需知情同意。43例患者(17例男性,26例女性;平均年龄46岁;年龄范围10 - 89岁),共46个脓肿,采用8.5 - 14F导管进行经皮引流。28个脓肿(60.9%)病因是术后,18个(39.1%)病因各异。若初始置管时内容物黏稠导致引流极少,或随访影像显示尽管导管位置满意但仍有大量残留积液,则开始腔内注射tPA。一个治疗周期为每日两次,连续3天,每次在0.9%盐水中注入4 - 6mg tPA。引流成功定义为无需手术即可排空脓肿。根据并发症评估安全性。采用Student t检验和Fisher精确检验进行统计分析。
46个脓肿最初由51根导管引流。41个(89.1%)脓肿实现完全排空,而5个(10.9%)需要手术引流。这5个中有3个(60%)记录有瘘管,比例高于成功引流的脓肿(P = 0.02)。46个脓肿中有3个(6.5%)复发(拔管后12 - 95天)。尽管4例患者接受了全剂量全身抗凝,24例接受了预防性抗凝,但未出现与tPA相关的出血并发症。
腔内注射tPA用于引流复杂积液安全有效,大多数患者无需手术。